BRIEF published on 07/31/2025 at 09:22, 5 months 28 days ago Sensorion Announces Participation in Investor Conferences Biotechnology Investor Conferences Sensorion Hearing Therapies September-October 2025
BRIEF published on 07/01/2025 at 07:35, 6 months 27 days ago Sensorion Reports Positive Preliminary Data from Audiogene Phase 1/2 Trial Gene Therapy Sensorion SENS-501 Congenital Deafness Audiogene Trial
PRESS RELEASE published on 07/01/2025 at 07:30, 6 months 27 days ago Inside Information / Other news releases Sensorion announces positive data from the first cohort of the Audiogene Phase 1/2 Gene Therapy Clinical Trial, showing safety and hearing improvement in toddlers. Second cohort recruitment near completion Gene Therapy Clinical Trial Sensorion Audiogene Hearing Improvement
BRIEF published on 05/13/2025 at 07:35, 8 months 15 days ago Sensorion Announces Approval of Shareholders’ Meeting Resolutions Biotechnology Gene Therapy Shareholder Resolutions Sensorion Hearing Loss Therapy
PRESS RELEASE published on 05/13/2025 at 07:30, 8 months 15 days ago Inside Information / Other news releases Sensorion announces successful adoption of all resolutions at Combined General Meeting. Results available on company's website Biotechnology Resolutions Combined General Meeting Sensorion Hearing Loss
BRIEF published on 05/06/2025 at 07:35, 8 months 22 days ago Sensorion to Present at ASGCT Annual Meeting Gene Therapy Sensorion Hearing Loss ASGCT Meeting DFNB1A
PRESS RELEASE published on 05/06/2025 at 07:30, 8 months 22 days ago Inside Information / Other news releases Sensorion announces participation at ASGCT Annual Meeting to present gene therapy research for hearing loss. Company focuses on developing innovative therapies. ASGCT 28th meeting details included Research Gene Therapy ASGCT Sensorion Hearing Loss
BRIEF published on 04/25/2025 at 07:35, 9 months 3 days ago Sensorion's Gene Therapy Presentation at 2025 ASPO Annual Meeting Gene Therapy Clinical Trial Hearing Loss SENS-501 Pediatric Otolaryngology
PRESS RELEASE published on 04/25/2025 at 07:30, 9 months 3 days ago Inside Information / Other news releases Sensorion announces Pr. Natalie Loundon presenting at 2025 ASPO Annual Meeting on SENS-501 gene therapy for hearing loss in children with DFNB9, Audiogene trial details and Sensorion's focus on developing therapies for hearing loss disorders Gene Therapy Sensorion Hearing Loss Audiogene Trial Pr. Natalie Loundon
BRIEF published on 04/18/2025 at 09:29, 9 months 10 days ago Sensorion prepares its General Meeting of May 12, 2025 Shareholders Biotechnology General Meeting Sensorion Hearing Loss
Published on 01/29/2026 at 03:30, 1 hour 47 minutes ago NuRAN Provides Clarification and Corrections Regarding Restructuring Transaction Disclosure
Published on 01/29/2026 at 02:15, 3 hours 2 minutes ago McEwen Inc. to Acquire Golden Lake Exploration Inc.
Published on 01/29/2026 at 01:50, 3 hours 27 minutes ago Alphinat Announces a Net Profit of $89,282 for Quarter Ended November 30, 2025
Published on 01/29/2026 at 00:00, 5 hours 17 minutes ago Tokenwell Adds Single-Coin Trading Capabilities and Expands Exchange Support
Published on 01/28/2026 at 23:45, 5 hours 32 minutes ago CoTec Holdings Corp. Announces Warrant Exercise by Kings Chapel
Published on 01/28/2026 at 19:00, 10 hours 16 minutes ago EQS-Adhoc: DWS Group GmbH & Co. KGaA: DWS raises mid-term targets and proposes payment of extraordinary dividend in 2027
Published on 01/28/2026 at 18:30, 10 hours 46 minutes ago Natus introduces AVEMG innovation in launch of latest edition of Natus Elite software
Published on 01/28/2026 at 17:58, 11 hours 18 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 01/28/2026 at 18:00, 11 hours 17 minutes ago Launch of Skira Education Systems and acquisition of Institut Beau Cèdre
Published on 01/28/2026 at 17:45, 11 hours 32 minutes ago Infotel : Q4 2025 revenue up +3.5%. Acquisition of Sesin, a specialist in EDM. A promising start to 2026
Published on 01/28/2026 at 17:40, 11 hours 37 minutes ago Mersen: Sales of €1.2 billion in 2025, in line with expectations
